New hope for lung cancer patients Who've run out of options?

NCT ID NCT07306624

Recruiting now Disease control Sponsor: STCube, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This phase 2 trial tests a new drug called nelmastobart combined with the chemotherapy docetaxel in 62 people with advanced non-small cell lung cancer that no longer responds to platinum chemo or immunotherapy. The goal is to see if the combination can slow cancer growth and improve survival. Participants must have a specific marker (BTN1A1 TPS score ≥50) to join.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nelmastobart and docetaxel
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced lung cancer who have stopped responding to standard therapies.
What could go wrong: This is an early-phase trial with only 62 participants, so results may not apply to everyone. The combination may cause side effects and might not improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Kangbuk Samsung Hospital
RECRUITING

Seoul, South Korea
Korea University Anam Hospital
RECRUITING

Seoul, South Korea
Samsung Medical Center
RECRUITING

Seoul, South Korea
Seoul National University Bundang Hospital
RECRUITING

Seoul, South Korea
The Catholic University of Korea St. Vincent's Hospital
RECRUITING

Gyeonggi-do, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.